Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 68-74

  Harris, Shannon L ^a   Zhu, Duzhang ^a   Murphy, Ellen ^a   McNeil, Lisa K ^a   Wang, Xin ^b   Mayer, Leonard W ^b   Harrison, Lee H ^c,d   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a Pfizervaccine Research   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

fHBP; Neisseria meningitidis serogroup C; Vaccine

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; BIVALENT FACTOR H BINDING PROTEIN; FACTOR H BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENE MAPPING; HAPLORHINI; INFECTION PREVENTION; MALE; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; RABBIT; REVIEW;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BASE SEQUENCE; BLOOD BACTERICIDAL ACTIVITY; CLUSTER ANALYSIS; COMPLEMENT SYSTEM PROTEINS; DNA, BACTERIAL; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; MACACA FASCICULARIS; MALE; MEMBRANE PROTEINS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS, SEROGROUP C; RABBITS; SEQUENCE ANALYSIS, DNA;

EID: 84862907934     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14564     Document Type: Review

References (17)

1. WHO. Control of Epidemic Meningococcal Disease. Geneva: World Heather Organization 1998.
2. Hayrinen J, Jennings H, Raff HV, Rougon G, Hanai N, Gerardy-Schahn R, et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 1995; 171:1481-90.
3. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infection & Immunity 2004; 72:2088-100. (Pubitemid 38419922)
4. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, et al. Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitidis. J Infect Dis 2009; 200:379-89.
5. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-99. (Pubitemid 36350873)
6. Jiang HQ, Hoiseth SK, Harris SL, McNeil L, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010; 28:6086-93.
7. th International Pathogenic Neisseria Conference; 2008 Rotterdam, The Netherlands 2008; 213.
8. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal Factor H-Binding Protein Variants Expressed by Epidemic Capsular Group A, W-135 and X Strains from Africa. The Journal of Infectious Diseases 2009; 199:1360-8.
9. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States: implications for prevention of meningococcal disease. Clin Infect Dis 1998; 50:184-91.
10. th European Meningococci Disease Society (EMGM) meeting Manchester, UK 2009.
11. McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009; 27:3417-21.
12. th International Pathogenic Neisseria Conference Rotterdam, The Netherlands 2008.
13. Brehony C, Wilson DJ, Maiden MCJ. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 2009; 155:4155-69.
14. thInternational Pathogenic Neisseria Conference (IPNC); 2010; Banff, Canada 2010.
15. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. Available at: www.cdc.gov/abcs/index.html. Accessed July 29 2010.
16. Liu X, Wang S, Sendi L, Caulfield MJ. Highthroughput imaging of bacterial colonies grown on filter plates with application to serum bactericidal assays. Journal of Immunological Methods 2004; 292:187-93. (Pubitemid 39179874)
17. Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, Gusarova V, et al. Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem 2009; 284:8738-46.